Ordinary Rebalance | Solactive China Biotech Innovation Index | Effective Date 14th November 2022
In the ordinary rebalancing the following index composition will be implemented effective open 14.11.2022:
3SBIO INC |
ALPHAMAB ONCOLOGY |
BEIJING BOHUI INNOVATION B-A |
BEIJING SL PHARMACEUTICAL -A |
BEIJING TIANTAN BIOLOGICAL-A |
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO LTD |
BERRY GENOMICS CO LTD-A |
BGI GENOMICS CO LTD-A |
CANSINO BIOLOGICS INC |
CHANGCHUN HIGH & NEW TECH-A |
CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO LTD |
CHONGQING ZHIFEI BIOLOGICA-A |
CSPC PHARMACEUTICAL GROUP LTD |
DAAN GENE CO LTD-A |
GENSCRIPT BIOTECH CORP |
GETEIN BIOTECH INC-A |
GUANGZHOU WONDFO BIOTECH C-A |
HEBEI CHANGSHAN BIOCHEMICA-A |
HUALAN BIOLOGICAL ENGINEER-A |
JOINN LABORATORIES CHINA CO LTD |
KINTOR PHARMACEUTICAL LTD |
PACIFIC SHUANGLIN BIO-PHARMACY |
SHANGHAI RAAS BLOOD PRODUC-A |
SHANGHAI ZJ BIO-TECH CO LT-A |
SHENZHEN KANGTAI BIOLOGICA-A |
SICHUAN KELUN PHARMACEUTIC-A |
WALVAX BIOTECHNOLOGY CO-A |
WUHAN KEQIAN BIOLOGY CO LT-A |
WUXI BIOLOGICS CAYMAN INC |
ZAI LAB LTD |